Compare · head to head
Bicara Therapeutics vs Coherus Oncology
Coherus Oncology ranks higher overall — 360 rank 72 vs 43.
Coherus Oncology leads on Growth (60 vs 42) and Safety (61 vs 41). Bicara Therapeutics leads on Sentiment (57 vs 49). The two are close on Quality.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Small |
| ISIN | US0554771032 | US19249H1032 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 43 | 72 |
| Value | NR | NR |
| Quality | 52 | 53 |
| Growth | 42 | 60 |
| Safety | 41 | 61 |
| Sentiment | 57 | 49 |
| Quality details | ||
| Profitability | 53 | 55 |
| Cash Truth | NR | NR |
Bicara Therapeutics vs Janux TherapeuticsBicara Therapeutics vs Zenas BiopharmaBicara Therapeutics vs Castle BiosciencesBicara Therapeutics vs Vir BiotechnologyAdd a third stock →
Full analyses: Bicara Therapeutics · Coherus Oncology
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100